Skip to main content
. 2018 Dec 14;24(6):762–771. doi: 10.1634/theoncologist.2018-0590

Figure 1.

image

Adverse events among patients reporting moderate/severe/very severe (MSVS) symptoms. (A): Percent of patients reporting MSVS symptoms by dose reduction and no dose reduction. (B): Percent of patients reporting MSVS symptoms by discontinuation and no discontinuation.